Justin Kim
Stock Analyst at Oppenheimer
(2.29)
# 1,450
Out of 4,416 analysts
30
Total ratings
45.83%
Success rate
-1.61%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Reiterates: Outperform | $107 | $65.27 | +63.93% | 4 | Mar 4, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $60.23 | +44.45% | 5 | Feb 29, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $75 → $79 | $47.46 | +66.46% | 5 | Jan 30, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $43.44 | -40.15% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $4.21 | - | 2 | Oct 17, 2023 | |
| ZURA Zura Bio | Initiates: Outperform | $17 | $4.62 | +267.97% | 1 | Aug 25, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $5.10 | - | 5 | Nov 4, 2022 | |
| PHVS Pharvaris | Maintains: Outperform | $48 → $22 | $22.60 | -2.65% | 2 | Aug 23, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $4.45 | - | 4 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $41.97 | +40.58% | 1 | Jul 18, 2022 |
Cytokinetics
Mar 4, 2024
Reiterates: Outperform
Price Target: $107
Current: $65.27
Upside: +63.93%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $60.23
Upside: +44.45%
Apellis Pharmaceuticals
Jan 30, 2024
Maintains: Outperform
Price Target: $75 → $79
Current: $47.46
Upside: +66.46%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $43.44
Upside: -40.15%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $4.21
Upside: -
Zura Bio
Aug 25, 2023
Initiates: Outperform
Price Target: $17
Current: $4.62
Upside: +267.97%
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $5.10
Upside: -
Pharvaris
Aug 23, 2022
Maintains: Outperform
Price Target: $48 → $22
Current: $22.60
Upside: -2.65%
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.45
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $41.97
Upside: +40.58%